Cargando…
Risk factors for clinically significant diffuse parenchymal lung abnormalities persisting after severe COVID-19 pneumonia
BACKGROUND & OBJECTIVES: The risk factors for clinically significant diffuse parenchymal lung abnormalities (CS-DPLA) persisting after severe coronavirus disease 2019 (COVID-19) pneumonia remain unclear. The present study was conducted to assess whether COVID-19 severity and other parameters are...
Autores principales: | Dhooria, Sahajal, Arora, Siddhant, Chaudhary, Shivani, Sehgal, Inderpaul Singh, Prabhakar, Nidhi, Mohammad, Nasim, Sharma, Riya, Das, Prabir, Kumar, Yashwant, Garg, Mandeep, Puri, Goverdhan Dutt, Bhalla, Ashish, Muthu, Valliappan, Prasad, Kuruswamy Thurai, Agarwal, Ritesh, Aggarwal, Ashutosh Nath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443720/ https://www.ncbi.nlm.nih.gov/pubmed/37322633 http://dx.doi.org/10.4103/ijmr.ijmr_2360_22 |
Ejemplares similares
-
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
por: Dhooria, Sahajal, et al.
Publicado: (2022) -
Where there is a balloon, there is a way!
por: Muthu, Valliappan, et al.
Publicado: (2020) -
The Reversed Halo Sign and the Bronchus Sign: The Eyes See Only What the Mind Knows
por: Muthu, Valliappan, et al.
Publicado: (2019) -
Corticosteroids for Non-severe COVID-19: Primum Non Nocere
por: Muthu, Valliappan, et al.
Publicado: (2022) -
Barrier Protection during Airway Intubation
por: Sehgal, Inderpaul S, et al.
Publicado: (2020)